William Blair & Company
OCGN icon

William Blair & Company’s Ocugen OCGN Stock Holding History

William Blair & Company’s Portfolio OCGN Stock Details OCGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,954
Closed -$20.1K – 1854
2024
Q2 		$20.1K Hold
12,954
– – ﹤0.01% 1687
2024
Q1 		$21.2K Buy
+12,954
New +$10.9K ﹤0.01% 1677

Other funds holding OCGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

William Blair & Company's OCGN Position: Q3 2024 in Review

William Blair & Company sold out of Ocugen (OCGN) in Q3 2024, closing a stake of 12,954 shares — an estimated $20.1K sold.

William Blair & Company first reported a position in OCGN in Q1 2024 and held it in 2 quarters. The position peaked at $21.2K in Q1 2024. 115 funds tracked by Wall St. Rank hold OCGN as of Q3 2024.

  • William Blair & Company reported no remaining Ocugen position as of Q3 2024 after selling out during the quarter.
  • William Blair & Company sold 12,954 Ocugen shares in Q3 2024, an estimated $20.1K.
  • William Blair & Company first reported a position in Ocugen in Q1 2024 and held it in 2 quarters.
  • William Blair & Company's Ocugen position peaked at $21.2K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Ocugen as of Q3 2024.

Based on William Blair & Company's 13F filing for Q3 2024, filed 12 Nov 2024.